Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Next Previous
Trial Profile

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kura Oncology

    • Most Recent Events

    • 14 Dec 2021 Final Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2021 According to a Kura Oncology media release, Thomas Witzig is the study's lead investigator.
    • 13 Dec 2021 Results published in the Kura Oncology Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top